Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 2/20 | 0.33 |
| ▸ | ARG2 | P78540 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29244862 | 0.79 | LMNA (0.45) | LMNABLMKMT2ASMYD3EPHX2 | |
| SCHEMBL2345431 | 0.79 | LMNA (0.49) | LMNABLMKMT2ASMYD3EPHX2 | |
| Hydrochloric Acid SCHEMBL5114605 | 0.79 | LMNA (0.45) | LMNABLMKMT2ASMYD3EPHX2 | |
| SCHEMBL2345434 | 0.79 | LMNA (0.49) | LMNABLMKMT2ASMYD3EPHX2 | |
| SCHEMBL10132089 | 0.78 | LMNA (0.44) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL7373388 | 0.76 | SLC7A5 (0.47) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL7373390 | 0.76 | SLC7A5 (0.47) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL13457724 | 0.75 | EPHX2 (0.50) | LMNABLMKMT2ASMYD3EPHX2 | |
| SCHEMBL10132091 | 0.75 | LMNA (0.56) | LMNABLMKMT2ASMYD3EPHX2 | |
| SCHEMBL17690666 | 0.75 | EPHX2 (0.50) | LMNABLMKMT2ASMYD3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-05 | — | — | US | disclosed |
| US-11420949-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210024477-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210024477-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-01-28 | — | — | US | disclosed |
| US-10836737-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836737-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20160362386-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2016-12-15 | — | — | US | disclosed |
| US-20160362386-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2016-12-15 | — | — | US | disclosed |
| US-9428453-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428453-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-10836737-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-11420949-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-20210024477-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-20160362386-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | LMNA 3058/4885BLM 2721/4885KMT2A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.